Advertisement
Advertisement
U.S. Markets close in 56 mins
Advertisement
Advertisement
Advertisement
Advertisement

Strongbridge Biopharma plc (SBBP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.0000+0.0300 (+1.52%)
As of 03:00PM EST. Market open.
Advertisement

Strongbridge Biopharma plc

900 Northbrook Drive
Suite 200
Trevose, PA 19053
United States
610 254 9200
http://www.strongbridgebio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees72

Key Executives

NameTitlePayExercisedYear Born
Mr. John H. JohnsonCEO & Director1.13MN/A1958
Dr. Fredric CohenChief Medical Officer784.11kN/A1965
Mr. Richard S. Kollender CPA, CPA, M.B.A.Pres & CFON/AN/A1969
Dr. Per Marin M.D., Ph.D.Founder and Sr. Clinical AdvisorN/AN/AN/A
Mr. Peter J. ValentinssonSr. VP of Global Technical OperationsN/AN/AN/A
Mr. Stephen J. LongChief Legal Officer & Company Sec.N/AN/A1966
Mr. Brian ConnerChief Compliance OfficerN/AN/AN/A
Mr. Dave BonnellSr. VP of SalesN/AN/AN/A
Ms. Emily DoyleChief HR OfficerN/AN/AN/A
Mr. Scott L. WilhoitChief Commercial OfficerN/AN/A1963
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that has completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.

Corporate Governance

Strongbridge Biopharma plc’s ISS Governance QualityScore as of July 1, 2021 is 6. The pillar scores are Audit: 8; Board: 6; Shareholder Rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement